AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00474916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KRN5500
Description: Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo . The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.
Study NCT00474916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline given as dose escalation for placebo
Study NCT02867696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Subjects in this arm will receive the standard care that is provided by their bariatric surgical team following bariatric surgery.
Study NCT02867696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-based Intervention (TECH)
Description: Dietary recommendations: based on the subjects' baseline body weight, with calorie goals ranging from 1200-2100 kcal/day.~The physical activity component: unsupervised home-based exercise program. Intensity/Mode: aerobic physical activity recommended at a moderate intensity. Prescription: progress to 250 min/wk by 13th week of the intervention.~Self-monitoring: Jawbone UP3 System includes a wearable device to monitor physical activity and energy expenditure that will transmit real-time feedback on calories expended and physical activity directly to a smart phone. An integrated digital smart scale will also be provided.~Contact: scheduled intervention telephone call: Month 1: One call per week for the first 4 weeks of the study; Months 2-6: One call per month.
Study NCT02588378 — intervention group
Intervention type: PROCEDURE
Intervention: multi-modal cSLO imaging
Study NCT03789006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithymocyte Immunoglobulin (Rabbit)
Description: Induction agent for living donor kidney transplantation
Study NCT03789006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin 2 Receptor Antagonist
Description: Induction agent for living donor kidney transplantation
Study NCT01045200 — intervention group
Intervention type: OTHER
Intervention: Comparison of follow-up
Description: Comparison of follow-up by nurse or surgeon after rectal cancer surgery
Study NCT05462678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation
Description: Each patient performed two weekly sessions of 45 minutes each, for 12 weeks
Study NCT05462678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Rehabilitation
Description: Each patient performed one session per week (45 minutes) of CR and one session per week of traditional MR training for 12 weeks.
Study NCT05462678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Rehabilitation
Description: Each patient performed two weekly sessions45 minutes each, for a total of 12 weeks.
Study NCT03903757 — intervention group
Intervention type: OTHER
Intervention: DNA methylome and total RNA sequencing
Description: Epigenomics tools combined with bioinformatic analysis to correlate putative useful clinical biomarkers with clinical features
Study NCT00184587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil
Study NCT00184587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02490657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost
Description: Nebulized agents (Iloprost or normal saline) were randomized by computer-generated randomization. The patients and anesthesiologist, who administered inhalation and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication, was the only person recognizing of the randomization code during trial.~Enrolled patients were received 20 μg iloprost or placebo (norma saline). Iloprost was diluted in normal saline to obtain 2ml solution. Control group were inhaled comparable dose of normal saline. Iloprost or normal saline was inhaled through an ultrasonic nebulized system in inspiratory limb.
Study NCT02490657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline (Saline 0.9%)
Study NCT02627716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SOS Plan
Description: It is a customised procedure that involves a meeting (crisis planning meeting) with the patient, their various medical and social referrers and any other person who they may have desired to invite.~The booklet outlines four avenues to consider:~* Contact details / contact person~* Treatment and current follow-ups~* Medical care in the event of a crisis~* Practical aid in the event of a crisis~Updating the SOS Plan every 6 months in the absence of hospitalisation or after each relapse that leads to an unscheduled psychiatric hospitalisation lasting more than two weeks.
Study NCT02331576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rocaine
Study NCT02331576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocaine
Study NCT02331576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study NCT01355289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Study NCT01355289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avatrombopag
Study NCT01355289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01355289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (PEG-IFN)
Description: Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.
Study NCT01355289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon (PEG-IFN)
Description: Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.
Study NCT01355289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
Study NCT01355289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Description: Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
Study NCT03199105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative education with image illustrations and/or local tetracaine mucilage
Description: The patients were given preoperative education with image illustrations and/or local tetracaine mucilage to alleviate CRBD during the post-operative period.
Study NCT00997529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonmyeloablative stem cell transplant
Description: Conditioning includes cytoxan 60mg/kg/d on Days 6 \& 5, total dose 120mg/kg, Fludarabine 25mg/m2/d on days -5 to -1, total dose 125mg/m2. Patients with decreased cardiac or liver function pre-transplant will have their dose of cytoxan reduced by 25% - 45 mg/kg/d for 2 days or total dose of 90mg/kg. Patients will receive G-CSF (5ug/kg) to foster engraftment. PBSC progenitors will be mobilized from donor with G-CSF 5ug/kg 2x daily starting 4 days prior to stem cell collection until a target of 5-10 x106 CD34+ cells/kg is reached. Peripheral blood progenitors will be isolated from leukaphereses obtained on Days 5 \& 6 with additional collections dependent on cell yields. Peripheral blood from donors will be given to patients 1 day after cytoreduction \& immunosuppression. Immunosuppression will be tapered Day +60 if no signs of GVHD. Patients with residual non-regressing disease or mixed chimerism after day 100, who are off immunosuppression \& do not have signs of GVHD, will receive a DLI
Study NCT02756442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory disorder assessment during sleep
Study NCT02756442 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory disorder assessment during sleep
Study NCT04581512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0042
Description: EP0042 Oral 20 mg 50 mg capsules
Study NCT00283959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat HCl
Study NCT02402036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib orally for 21 days every 28 day cycle
Study NCT03381742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: clopidogrel 75 mg once daily for 5 consecutive days at least.
Study NCT04507373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin 40mg
Description: 40mg oral daily for 10 weeks
Study NCT04507373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 40mg
Description: 40mg oral daily for 10 weeks
Study NCT04450810 — intervention group
Intervention type: OTHER
Intervention: Observation of serum and salivary NLRP3 levels
Description: Evaluation of serum and salivary NLRP3 levels
Study NCT03923803 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: C- reactive protein
Description: the measurement will be done by chemileumeniscence
Study NCT03923803 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pro calcitonin
Description: the measurement will be done by chemileumeniscence
Study NCT02955251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-428
Description: ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.
Study NCT02955251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered by intravenous infusion according to approved dose and dosing schedules.
Study NCT01097200 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Elevate mesh
Description: The correction of the prolapse can be made by this new technique.
Study NCT01097200 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sacrocolpopexy
Description: Attach a mesh between the vagina and the promontorium.
Study NCT01653379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP001
Description: DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
Study NCT00830869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXAZOMIB
Description: All participants will receive IXAZOMIB IV injection on Days 1, 4, 8, and 11 of each treatment cycle followed by a rest period of 10 days.~The first stage of the study will be initiated at a starting dose of 0.125 mg/m\^2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established.
Study NCT04689412 — intervention group
Intervention type: DRUG
Intervention: Resveratrol
Description: Nasal administration of resveratrol
Study NCT02427178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Allogeneic Stem Cells
Description: HLA 10/10 matched allogeneic bone marrow cells will be infused into recipient (patient).
Study NCT00130312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulodexide
Description: 100 mg gelcap in the morning and evening
Study NCT00130312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo gelcap in the morning and evening
Study NCT03363022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment includes antibiotics,CRRT (Continuous Renal replacement Therapy),Liver Dialysis.
Study NCT03363022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment includes antibiotics,CRRT (Continuous Renal replacement Therapy),Liver Dialysis.
Study NCT03363022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Fecal Microbiota Transplant Stool specimen (preferably Bristol Stool Type 3 or 4) with a weight of ∼50 g will be considered adequate.~250 mL sterile normal saline will be added to the stool sample and homogenized with a blender for 2-4minutes in pulses of 30 seconds with 10 seconds wait in between each pulse.~Enema to be held for 30 minutes.
Study NCT03363022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be identical and non medicinal to the Fecal Microbiota Transplant
Study NCT04779749 — intervention group
Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files
Study NCT03821662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OT Diabetes Self-Management Intervention
Description: Occupational therapy chronic disease self-management intervention.
Study NCT03386877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal regeneration
Description: Defects were accessed with the MIST In the test group the obtained micro-grafts enriched in DPSCs were endorsed onto a collagen sponge scaffold (Condress®, Istituto Gentili, Milano, Italy) to form a bio-complex. In the control group the collagen sponge was only hydrated using physiologic sterile solution. The collagen sponge with or without cells was provided to the masked surgeon who filled the intrabony defect. The flaps were repositioned and tension-free primary flap closure was obtained using horizontal internal mattress and interrupted sutures
Study NCT03386877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periodontal regeneration
Description: Defects were accessed with the MIST In the test group the obtained micro-grafts enriched in DPSCs were endorsed onto a collagen sponge scaffold (Condress®, Istituto Gentili, Milano, Italy) to form a bio-complex. In the control group the collagen sponge was only hydrated using physiologic sterile solution. The collagen sponge with or without cells was provided to the masked surgeon who filled the intrabony defect. The flaps were repositioned and tension-free primary flap closure was obtained using horizontal internal mattress and interrupted sutures
Study NCT03348592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (p-inulin)
Study NCT03348592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment
Description: Patients do not take a supplement during the first 8 weeks or the last 8 weeks of the study.
Study NCT05512468 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: carbon dye
Description: Tattooing (marking) of biopsied node with carbon dye at the time or at a separate session of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
Study NCT00743236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cold ischemia procedure
Description: Cold ischemia followed by partial nephrectomy
Study NCT04235855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic USG guided Liver biopsy
Description: Diagnostic yield with EUS guided liver biopsy - Left lobe Bx vs combined right and left lobe or vs right lobe would be assessed.
Study NCT04235855 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Liver Biopsy
Description: All liver biopsies done in the Institute as routine procedure by percutaneous route would be compared with the EUS guided biopsy in respect to safety , tissue quality and diagnostic yield .
Study NCT02347787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPaCT
Description: The IMPaCT intervention has three stages:~1. Goal-setting: CHWs will help patients to deconstruct the chronic disease management goal they set with their PCP into patient-driven short-term goals and action plans.~2. Tailored Support: CHWs will conduct weekly follow-up for 6 months through either telephone or home visit in order to support the achievement of patients' short-term goals.~3. Connection with longitudinal support: IMPaCT CHWs will also facilitate a weekly patient support group.
Study NCT02347787 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Study NCT04557644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7-items-questionnaires addressing CI, disgust and empathy
Description: 7-items-questionnaire including numerical rating scales (NRS) ranging from 0 (no itch/disgust/empathy) to 10 (worst itch/disgust/most empathy imaginable) to rate itch, disgust and empathy they experience when treating the infested families.
Study NCT04557644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saarbrucken Personality questionnaire (SPQ) addressing empathy.
Description: Empathy is additionally assessed by the Saarbrucken Personality Questionnaire (SPQ) ,a 16-item tool.
Study NCT01355289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
Study NCT01355289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
Study NCT02676258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Si-Hy (olifilcon B)
Description: Wear Si-Hy silicone hydrgel soft contact lens for 3 months
Study NCT02676258 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vistakon (narafilcon A)
Description: Wear Vistakon soft contact lens for 3 months
Study NCT00093236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Periodontal Treatment
Description: Subjects will receive scaling and root planing at baseline. Three weeks after initiation of the study, they will return and be re-evaluated for the need for periodontal surgery. If indicated, they will then receive definitive periodontal surgery over the next 4 weeks. At the 12-week time point, periodontal surgery will be reevaluated and further therapy provided as needed and make repeated visits as needed to achieve periodontal health.comprehensive periodontal treatment
Study NCT00093236 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Dental Hygiene
Description: Subjects will receive routine oral hygiene visits at the 3 and 12-week time points. After a 12-week period (24 week time point) to allow healing and resolution of a systemic inflammatory state, patients will return for follow-up measurements of periodontal parameters, vascular function and inflammation.
Study NCT00116454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131 I-lipiodol
Description: intra-arterial hepatic administration of Lipiocis will occur, 11 to 12 weeks after the initial curative treatment
Study NCT03906266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: NRS 2002, nutric, SGA and adductor pollicis
Description: NRS 2002, nutric, SGA and adductor pollicis tests detects the malnutrition
Study NCT03906266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NRS 2002, nutric, SGA and adductor pollicis
Description: NRS 2002, nutric, SGA and adductor pollicis tests detects the malnutrition
Study NCT03114033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted therapeutic mild hypercapnia
Description: Patients allocated to the TTMH protocol will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of -4). Arterial blood gases and end- tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 50-55 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change >5 mmHg
Study NCT03114033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Targeted normocapnia (Standard care)
Description: Patients allocated to the standard care (TN) protocol will be managed according to current practice and in accordance with ILCOR guidelines which recommend maintaining normocapnia in these patients. They will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of - 4). Arterial blood gases and end-tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 35-45 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change >5 mmHg.
Study NCT04557644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10-items-questionnaire addressing previous dermatological conditions, intensity of itch
Description: 10-items-questionnaire (completed by the hospitalised family) regarding demographic information (gender, age, profession), previous dermatological conditions, intensity of itch a.) on the first day of the hospitalisation, b.) when seeing the skin lesions of the other family members c.) when talking about the scabies/itch with the other family members, d.) when seeing other family members scratching themselves, and questions regarding their intensity of disgust of the scabies and empathy for the other family members (0-10 NRS).
Study NCT04557644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ItchyQol-questionnaire composed of 22 items addressing itch-related symptoms, functions and emotions
Description: ItchyQol-questionnaire to assess the itch-related quality of life impairment. The ItchyQoL is composed of 22 items addressing itch-related symptoms, functions and emotions.